Statins for primary prevention: what is the regulator's role?

Area of Science:

• Pharmacology
• Regulatory Science
• Cardiovascular Medicine

Background:

• Statins are widely approved for cardiovascular disease (CVD) prevention.
• Their use in primary prevention remains controversial, with ongoing debate about benefit-risk balance.
• Drug regulatory agencies have not publicly addressed this debate.

Purpose of the Study:

• To investigate European drug regulators' decision-making processes for statin approvals.
• To request and examine the data underpinning statin licensing.

Main Methods:

• Analysis of regulatory procedures across European countries.
• Inquiries regarding data accessibility and archival practices for statin approvals.

Main Results:

• European drug regulation for statins is fragmented; many nations license drugs without independent data analysis.
• No centralized, accessible archive exists for statin approval information or trial data.
• Current system lacks transparency and accessibility for the public and researchers.

Conclusions:

• The fragmented regulatory system for statins is unsustainable.
• Improved data accessibility and centralized archiving are needed for public trust and scientific advancement.
• Regulatory bodies must enhance transparency in drug approval processes.